« Return to News | Drug Sponsors

Lycera partners with Merck

Thursday, March 3, 2011 03:17 PM

Plymouth, Mich.-based Lycera will receive $12 million upfront and up to $295 million in milestone payments from Merck in a collaboration to discover new anti-inflammatory drugs, according to FierceBiotech. The deal is focused on new small molecules that target T-helper 17 (Th17) cells, key mediators of inflammation and a new approach to treating major autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and multiple sclerosis.

"We are delighted to be working with Merck, which brings industry leading expertise in drug discovery, development and commercialization to this collaboration," said Gary Glick, Lycera founder and chief scientific officer. "This joint partnership is a significant validation of Lycera's discovery capabilities and our Th17 program, and enables us to expand the scope of our research in this promising area to expedite our discovery efforts as well as our timeline to enter the clinic."

Lycera's technology is built around the observation that mice with RORγt deficient T cells lack Th17 cells, which produce the inflammatory cytokine interleukin-17. And by targeting Th17, it has been able to reduce the production of IL-17 in cells and in vivo. Lycera was launched four years ago and has raised $36 million in venture funding.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.